For the quarter ending 2026-03-31, ALGS had $11,741K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net (loss) income, as reported | -23,040 | -19,881 | -31,537 | 27,225 |
| Accretion of discount on investments | 419 | 444 | 710 | 1,034 |
| Non cash lease expense | 509 | 492 | 478 | 905 |
| Change in fair value of 2023 common warrants | -3,395 | -1,213 | 4,205 | -63,176 |
| Depreciation expense | 346 | 257 | 220 | 453 |
| Stock-based compensation including espp | 1,314 | 1,458 | 1,467 | 2,119 |
| Deferred revenue | - | -168 | -411 | 428 |
| Accounts payable | 3,657 | -669 | 752 | 1,328 |
| Accrued liabilities | -1,537 | -79 | 1,400 | -3,352 |
| Operating lease liabilities | -834 | -817 | -796 | -1,499 |
| Other liabilities | -47 | - | - | - |
| Other assets | -318 | 681 | -587 | -190 |
| Net cash and cash equivalents used in operating activities | -23,128 | -21,745 | -24,345 | -36,413 |
| Maturities of short-term investments | 35,000 | 37,500 | 70,000 | 20,000 |
| Purchase of short-term investments | - | 39,429 | 22,124 | 103,336 |
| Purchases of property and equipment | -69 | -92 | -193 | -152 |
| Net cash and cash equivalents provided by (used in) investing activities | 34,931 | -2,021 | 47,683 | -83,488 |
| Proceeds from the espp purchase | - | 124 | 0 | 180 |
| Proceeds from issuance of common stock, common warrants and pre-funded warrants in connection with pipe offering, net of costs | - | 2 | -43 | 101,386 |
| Payments on finance lease | 62 | 3 | 10 | 1 |
| Net cash and cash equivalents (used in) provided by financing activities | -62 | 123 | -53 | 101,565 |
| Net increase in cash, cash equivalents, and restricted cash | 11,741 | -23,643 | 23,285 | -18,336 |
| Cash, cash equivalents, and restricted cash, beginning of period | 18,413 | 42,056 | 37,107 | - |
| Cash, cash equivalents, and restricted cash, end of period | 30,154 | 18,413 | 42,056 | - |
Aligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics, Inc. (ALGS)